CureVac AG

CureVac AG : German mRNA company with a diversified pipeline; Ph 2a trial ongoing with COVID-19 vaccine candidate, CVnCoV. Global Ph 2/3 trial enrolling approx. 36,500 participants with results expected 1Q21. Three other programs in Ph 1: CV8102 (cutaneous melanoma, adenoidcystic carcinoma, squamous cell cancer of skin, head & neck), CV9202 (NSCLC) and CV7202 (Rabies). mRNA-based antibody delivery deal with Genmab (Dec'19). Other strategic partnerships include GSK and CRISPR Tx.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III
Disease Space
Anti-infectives, Antivirals, Autoimmune, COVID-19, Infectious Disease, Oncology, Ophthalmology
Finance
Pre-Revenues
Industry
Biotechnology
Investement Strategy
Under the Radar
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Platform Technology, Vaccine
Website:
Profiles:
Address:
Paul-Ehrlich-Straße 15
Tübingen, Baden-Wurttemberg 72076
Germany

Company Participants at 2020 Wall Street "On Tap"

Franz-Werner Haas
CureVac AG, Chief Executive Officer, Chief Operating Officer
Franz-Werner Haas joined CureVac in June 2012. Before joining CureVac, he was Vice President Operations and Chief Compliance Officer of SYGNIS Pharma AG, where he was responsible for the execution of M&A and capital market transactions. Franz-Werner started his professional career as an assistant to the management of a privately-held holding company before assuming several management positions in the Life Science Industry, including Vice President and General Counsel of LION bioscience and General Counsel of Sirona Dental Systems. He studied law at the University of Saarbruecken, K.U. Leuven and the University of Edinburgh (LL.M.).

Top 10 Holders of CureVac N.V.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Baillie Gifford & Co. 2.19 3,896,475 391.01 13F 9/30/20
T. Rowe Price Associates, Inc. (Investment Management) 0.68 1,202,421 120.66 13F 9/30/20
DekaBank Deutsche Girozentrale 0.24 435,500 43.70 13F 9/30/20
Samsara Biocapital LLC 0.21 370,385 37.17 13F 9/30/20
Millennium Management LLC 0.17 304,637 30.57 13F 9/30/20
Novo Holding A/S 0.11 201,642 20.23 13F 9/30/20
Hillhouse Capital Advisors Ltd. (Cayman Islands) 0.10 186,183 18.68 13F 9/30/20
Vivo Capital LLC 0.10 169,825 17.04 13F 9/30/20
Geode Capital Management LLC 0.07 130,878 13.13 13F 9/30/20
Susquehanna Securities LLC 0.07 125,536 12.60 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.